Viktoria Blumenberg, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 17 | 2024 | 1455 | 1.860 |
Why?
|
| Antigens, CD19 | 11 | 2023 | 424 | 1.270 |
Why?
|
| Candida glabrata | 1 | 2021 | 37 | 0.730 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 7 | 2023 | 1403 | 0.720 |
Why?
|
| Aspergillus fumigatus | 1 | 2021 | 156 | 0.670 |
Why?
|
| Anemia, Aplastic | 1 | 2021 | 228 | 0.640 |
Why?
|
| Lymphoma | 5 | 2023 | 1899 | 0.560 |
Why?
|
| Receptors, Antigen, T-Cell | 7 | 2024 | 2536 | 0.530 |
Why?
|
| Leukemia | 1 | 2022 | 1523 | 0.460 |
Why?
|
| Lymphoma, B-Cell | 3 | 2023 | 935 | 0.390 |
Why?
|
| Neurotoxicity Syndromes | 3 | 2022 | 299 | 0.330 |
Why?
|
| T-Lymphocytes | 8 | 2024 | 10181 | 0.270 |
Why?
|
| Biological Products | 3 | 2021 | 916 | 0.220 |
Why?
|
| Blood Component Removal | 1 | 2023 | 132 | 0.210 |
Why?
|
| Immunity, Humoral | 1 | 2023 | 604 | 0.160 |
Why?
|
| Sarcopenia | 1 | 2023 | 372 | 0.150 |
Why?
|
| Hematologic Diseases | 1 | 2021 | 497 | 0.150 |
Why?
|
| Intra-Abdominal Fat | 1 | 2022 | 607 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2021 | 1832 | 0.130 |
Why?
|
| Salvage Therapy | 1 | 2022 | 1268 | 0.130 |
Why?
|
| Neoplasms | 4 | 2023 | 22075 | 0.110 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2022 | 916 | 0.110 |
Why?
|
| Body Composition | 1 | 2022 | 2419 | 0.110 |
Why?
|
| Interleukin-6 | 1 | 2022 | 3215 | 0.100 |
Why?
|
| Recurrence | 1 | 2022 | 8483 | 0.090 |
Why?
|
| Humans | 21 | 2024 | 760613 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2023 | 2007 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2021 | 5349 | 0.050 |
Why?
|
| Polyamines | 1 | 2022 | 133 | 0.050 |
Why?
|
| Intermediate Filaments | 1 | 2022 | 172 | 0.050 |
Why?
|
| Leukapheresis | 1 | 2021 | 134 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 9278 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2023 | 2262 | 0.040 |
Why?
|
| Prognosis | 3 | 2023 | 29661 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 2021 | 655 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2021 | 1351 | 0.040 |
Why?
|
| Positron-Emission Tomography | 2 | 2023 | 6465 | 0.040 |
Why?
|
| Retrospective Studies | 5 | 2023 | 80345 | 0.030 |
Why?
|
| Neutropenia | 1 | 2021 | 884 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2023 | 2611 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2023 | 2935 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 1174 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2023 | 5869 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2023 | 2896 | 0.030 |
Why?
|
| Middle Aged | 3 | 2023 | 220359 | 0.030 |
Why?
|
| Anemia | 1 | 2021 | 1511 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2022 | 5201 | 0.020 |
Why?
|
| Vaccination | 1 | 2023 | 3359 | 0.020 |
Why?
|
| Stem Cells | 1 | 2022 | 3524 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2023 | 3527 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2023 | 4642 | 0.020 |
Why?
|
| Male | 2 | 2023 | 359718 | 0.020 |
Why?
|
| Cytokines | 1 | 2021 | 7344 | 0.020 |
Why?
|
| Disease Progression | 1 | 2022 | 13505 | 0.020 |
Why?
|
| Incidence | 1 | 2021 | 21391 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2023 | 24102 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2022 | 54306 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 58980 | 0.010 |
Why?
|
| Young Adult | 1 | 2021 | 58748 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2021 | 64981 | 0.010 |
Why?
|
| Mice | 1 | 2021 | 81209 | 0.010 |
Why?
|
| Animals | 1 | 2021 | 167960 | 0.010 |
Why?
|
| Aged | 1 | 2021 | 169143 | 0.010 |
Why?
|
| Adult | 1 | 2021 | 220007 | 0.000 |
Why?
|
| Female | 1 | 2023 | 391246 | 0.000 |
Why?
|